Arcutis Biotherapeutics, Inc. (ARQT) vs Iovance Biotherapeutics, Inc. (IOVA)

Arcutis Biotherapeutics, Inc. and Iovance Biotherapeutics, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Iovance Biotherapeutics, Inc. are of similar size ($3.5B and $3.4B). Iovance Biotherapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 119×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 60.0% against 51.3%. Arcutis Biotherapeutics, Inc. has the higher net margin (5.88% vs −58.2%) and the higher return on invested capital (23.5% vs −17.7%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 13 and Iovance Biotherapeutics, Inc. on 4.

Valuation

Metric ARQT IOVA Biotechnology median
P/E 118.96 n/m 10.26
P/S 7.02 9.29 9.18
P/B 14.64 4.33 2.05
Price to free cash flow 79.88 n/m 24.81
EV/EBITDA 92.82 n/m 0.65
EV/Sales 6.72 8.51 8.98
Earnings yield 0.84% (6.78%) (34.89%)
Free cash flow yield 1.25% (6.14%) (24.52%)

Profitability

Metric ARQT IOVA Biotechnology median
Gross margin 91.18% 0.00% 65.16%
Operating margin 6.91% (60.79%) 0.00%
Net margin 5.88% (58.19%) 0.00%
Free cash flow margin 11.74% (57.01%) 0.00%
Return on equity 14.88% (29.11%) (50.12%)
Return on assets 6.68% (23.26%) (45.60%)
Return on invested capital 23.48% (17.72%) 0.00%

Growth

Metric ARQT IOVA Biotechnology median
Revenue growth (TTM) 60.00% 51.34% 6.26%
EPS growth (last fiscal year) 88.79% 14.84% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARQT IOVA Biotechnology median
Debt to equity 0.45 0.00 0.00
Current ratio 2.92 5.20 4.89
Net debt to EBITDA 11.64 0.82 1.01

Dividend

Metric ARQT IOVA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARQT IOVA Biotechnology median
Market cap 3.39b 3.51b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack